A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.

A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.

Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the Philadelphia chromosome, have drastically improved the outcomes for patients with chronic myeloid leukemia (CML). Although several real-time quantitative polymerase chain reaction (RQ-PCR) kits for the detection...

Full description

Bibliographic Details
Main Authors: Hiroaki Kitamura, Yoko Tabe, Tomohiko Ai, Koji Tsuchiya, Maiko Yuri, Shigeki Misawa, Takashi Horii, Atsushi Kawaguchi, Akimichi Ohsaka, Shinya Kimura
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0207170

Internet

https://doi.org/10.1371/journal.pone.0207170

Similar Items